BioCentury | Oct 10, 2016
Company News

Vivus, Mist Pharmaceuticals deal

...Vivus granted Mist’s Metuchen Pharmaceuticals LLC affiliate exclusive rights to commercialize erectile dysfunction drug Stendra avanafil...
...Vivus has rights from the pharma outside Japan, China and certain other Pacific Rim countries. Stendra...
BioCentury | Feb 16, 2015
Clinical News

Stendra avanafil regulatory update

...The European Commission approved a label expansion for Spedra avanafil for erectile dysfunction (ED) to indicate...
...activity, down from about 30 minutes before sexual activity. Avanafil is approved in U.S. as Stendra...
...Corp. (Tokyo:4508), Osaka, Japan Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: Stendra avanafil ( Spedra , Zepeed...
BioCentury | Oct 6, 2014
Company News

Auxilium endocrine/metabolic, genitourinary, musculoskeletal news

...a long-acting implantable testosterone replacement therapy; and erectile dysfunction drugs Edex alprostadil and Stendra avanafil...
...E1, and Stendra is a fast-acting phosphodiesterase-5 (PDE-5) inhibitor. Auxilium has exclusive commercialization rights to Stendra...
BioCentury | Sep 22, 2014
Clinical News

Stendra avanafil regulatory update

...said FDA approved an sNDA to amend the label of erectile dysfunction (ED) drug Stendra avanafil...
...to close next quarter (see BioCentury, June 30). Avanafil is also approved in Europe as Spedra...
...Corp. (Tokyo:4508), Osaka, Japan Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: Stendra avanafil ( Spedra , Zepeed...
BioCentury | Sep 19, 2014
Company News

Quicker label for Stendra boosts Vivus

...after FDA approved an sNDA to amend the label of erectile dysfunction (ED) drug Stendra avanafil...
...now recommends the drug be taken about 15 minutes before sexual activity; it previously indicated Stendra...
BioCentury | Aug 11, 2014
Strategy

Profusion of exclusions

...telmisartan and Micardis HCT telmisartan/hydrochlorothiazide (A) Boehringer Ingelheim GmbH ü Erectile dysfunction oral agents Stendra avanafil...
BioCentury | Jul 14, 2014
Finance

3Q14 Financial Markets Preview: Summer lull

...NDA and MAA 4Q14 Vivus Inc. (NASDAQ:VVUS)/Auxilium Pharmaceuticals Inc. (NASDAQ:AUXL)/Mitsubishi Tanabe Pharma Corp. (Tokyo:4508) Stendra avanafil...
BioCentury | Jun 30, 2014
Company News

QLT, Auxilium deal

...approved products, including Xiaflex collagenase clostridium histolyticum for Peyronie’s disease and Dupuytren’s contracture and Stendra avanafil...
BioCentury | Jun 27, 2014
Top Story

Auxilium to merge with QLT

...approved products, including Xiaflex collagenase clostridium histolyticum for Peyronie's disease and Dupuytren's contracture and Stendra avanafil...
BioCentury | May 19, 2014
Company News

Menarini, Vivus sales and marketing update

...In its 1Q14 earnings, Vivus disclosed that Menarini launched Spedra avanafil for erectile dysfunction in France...
...to disclose financial terms, including pricing information for the countries (see BioCentury, July 22, 2013). Spedra...
Items per page:
1 - 10 of 86